IRIS
LEMOLI, ROBERTO MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 28.639
AS - Asia 2.985
NA - Nord America 1.103
SA - Sud America 250
AF - Africa 56
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 33.040
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 28.016
SG - Singapore 1.385
US - Stati Uniti d'America 1.031
CN - Cina 828
VN - Vietnam 477
FR - Francia 270
BR - Brasile 156
FI - Finlandia 140
HK - Hong Kong 94
DE - Germania 63
AR - Argentina 41
JP - Giappone 39
GB - Regno Unito 32
MX - Messico 32
IQ - Iraq 24
CA - Canada 23
IN - India 23
CH - Svizzera 21
BD - Bangladesh 17
PH - Filippine 14
ID - Indonesia 13
NL - Olanda 13
UA - Ucraina 12
EC - Ecuador 11
KR - Corea 11
MA - Marocco 11
RU - Federazione Russa 10
CO - Colombia 9
ES - Italia 9
KE - Kenya 9
TR - Turchia 9
VE - Venezuela 9
IE - Irlanda 8
PY - Paraguay 8
UZ - Uzbekistan 8
CL - Cile 7
AU - Australia 6
EG - Egitto 6
TN - Tunisia 6
ZA - Sudafrica 6
PK - Pakistan 5
SE - Svezia 5
TH - Thailandia 5
GR - Grecia 4
NP - Nepal 4
UY - Uruguay 4
AL - Albania 3
AT - Austria 3
AZ - Azerbaigian 3
BE - Belgio 3
BG - Bulgaria 3
BO - Bolivia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
LT - Lituania 3
RO - Romania 3
SA - Arabia Saudita 3
SI - Slovenia 3
AO - Angola 2
BH - Bahrain 2
CY - Cipro 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
JO - Giordania 2
KZ - Kazakistan 2
LB - Libano 2
MD - Moldavia 2
MY - Malesia 2
NI - Nicaragua 2
PE - Perù 2
PL - Polonia 2
PS - Palestinian Territory 2
PT - Portogallo 2
BB - Barbados 1
CG - Congo 1
CI - Costa d'Avorio 1
GE - Georgia 1
GH - Ghana 1
GN - Guinea 1
GT - Guatemala 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MG - Madagascar 1
MT - Malta 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
RE - Reunion 1
RS - Serbia 1
Totale 33.032
Salva come PNG Salva come JPEG
Città #
Genova 16.750
Genoa 6.888
Rapallo 2.489
Vado Ligure 1.685
Singapore 641
San Jose 398
Lauterbourg 245
Ho Chi Minh City 149
Helsinki 131
Ashburn 130
Hanoi 104
Council Bluffs 99
Hong Kong 89
Beijing 85
Bordighera 61
Frankfurt am Main 54
New York 53
Santa Clara 38
Tokyo 31
Los Angeles 27
Tianjin 27
Haiphong 24
St Louis 20
São Paulo 20
Zurich 19
Da Nang 17
Rome 17
Mexico City 16
Orem 15
Paris 12
Baghdad 11
Hải Dương 11
Shanghai 11
Milan 10
Amsterdam 9
Lappeenranta 9
Chicago 8
Dublin 8
Guangzhou 8
Nairobi 8
Ninh Bình 8
City of London 7
Istanbul 7
Madrid 7
Montreal 7
Schiavon 7
Biên Hòa 6
Naples 6
Nuremberg 6
Tashkent 6
Toronto 6
Cardiff 5
Dallas 5
Hangzhou 5
London 5
Poplar 5
Quận Ba 5
Shenzhen 5
Turin 5
Ân Thi 5
Atlanta 4
Buenos Aires 4
Bắc Ninh 4
Can Tho 4
Chennai 4
Johannesburg 4
Kyiv 4
Marseille 4
Montevideo 4
Parma 4
Salvador 4
Sydney 4
Vĩnh Long 4
Điện Bàn 4
Athens 3
Baku 3
Barranquilla 3
Bologna 3
Boston 3
Brooklyn 3
Buffalo 3
Cairo 3
Caracas 3
Casablanca 3
Changsha 3
Chengdu 3
Conselheiro Lafaiete 3
Denver 3
Des Moines 3
Dhaka 3
Djursholm 3
Hortolândia 3
Ljubljana 3
Manchester 3
Merlo 3
Perugia 3
Phoenix 3
Phủ Lý 3
Porto Alegre 3
Quito 3
Totale 30.679
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 240
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 220
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 218
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 211
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 208
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 203
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 195
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 194
T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells. 193
Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma 192
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 189
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 179
Harnessing NK Cells for Cancer Treatment 170
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 170
T lymphocyte killing by a xanthine-oxidase-containing immunotoxin. 169
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 166
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 166
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 166
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients 166
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 164
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 163
C-kit ligand (SCF) in human multiple myeloma cells. 163
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 162
Viability of autologous bone marrow. 159
Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. 158
CD103 Marks a Subset Of Human CD34+-Derived Langerin+ Dendritic Cells Which Induce T Regulatory Cells Via Indoleamine 2,3-Dioxygenase-1. 158
Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma 158
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 157
The sixth sense: hematopoietic stem cells detect danger through purinergic signaling. 155
A novel model of CCl4-induced cirrhosis with ascites in the mouse. 155
Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. 155
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. 154
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 154
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. 154
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 154
Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. 152
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 152
Allogeneic hematopoietic stem cells from sources other than bone marrow: biological and technical aspects. 150
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 150
The CD47 pathway is deregulated in human immune thrombocytopenia. 149
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 149
Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients. 148
The P2X7 receptor: a key player in IL-1 processing and release. 148
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia 147
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 146
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas 146
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 146
Autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma: comparison of different parameters in predicting the kinetics of haematological recovery. 144
Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes 144
Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. 143
Haploientical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography 143
Autologous bone marrow transplantation with marrow cryopreserved for ten years. 142
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. 142
Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia 141
Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. 140
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. 140
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 140
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 140
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. 139
Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. 139
Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. 139
Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: A GITMO survey on 809 patients autografted in first complete remission 139
Feasibility of Single-Port Laparoscopic Lymph Node Biopsy for Intra-Abdominal Lymphoma: A Case Series 139
Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. 138
Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. 137
Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. 137
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study 137
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 137
Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma. 136
Interleukin-11 induces Th2 polarization of human CD4(+) T cells. 136
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. 136
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. 136
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 136
Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF). 135
Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. 135
Cryopreserved autologous bone marrow transplantation in patients with acute nonlymphoid leukemia: chemotherapy before harvesting is the main factor in delaying hematological recovery. 134
Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. 134
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 134
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 133
Characterization of autotransplant-related thrombocytopenia by evaluation of glycocalicin and reticulated platelets. 133
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. 133
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 132
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 132
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 132
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. 132
Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. 132
Purging in autologous and allogeneic bone marrow transplantation. 132
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial 132
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. 132
Stem cell plasticity: time for a rappraisal? 131
Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection. 131
Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. 131
Pharmacological elimination of tumor cells contaminating normal human bone marrow using PTT-119. 131
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib 131
FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report. 130
Generation and functional characterization of human dendritic cells derived from CD34 cells mobilized into peripheral blood: comparison with bone marrow CD34+ cells. 130
In vitro growth of myeloma cells. 130
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 130
Improvement of human myeloma stem cell growth in a liquid culture system supplemented with phytohemagglutinin. 130
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. 130
Totale 15.103
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.128
article - articoli 98.237
book - libri 0
conference - conferenze 657
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.234
Totale 202.256
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021454 0 0 0 0 0 0 0 0 0 202 99 153
2021/20222.954 57 121 67 360 234 231 233 647 111 287 80 526
2022/20233.127 357 279 68 357 474 525 5 266 486 31 224 55
2023/20241.464 66 180 71 165 109 277 99 142 77 29 78 171
2024/20254.282 62 368 169 301 529 418 455 566 145 255 428 586
2025/20267.554 864 348 661 763 978 869 1.348 392 642 689 0 0
Totale 33.474